ABBV vs GEV: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and GE Vernova Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-07-25.
AbbVie Inc. · Healthcare
$261.07
+1.2% upside to fair value
Grade C
High Quality
VS
GE Vernova Inc. · Industrials
$1,014.75
-16.2% upside to fair value
Med Conviction
Grade C+
QuantHub Verdict
ABBV has more upside to fair value
(+1.2%).
GEV trades at a lower forward P/E
(34.3x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
GEV |
| Current Price |
$261.07 |
$1,014.75 |
| Fair Value Estimate |
$264.30 |
$850.00 |
| Upside to Fair Value |
+1.2%
|
-16.2%
|
| Market Cap |
$461.3B |
$270.3B |
| Forward P/E |
128.0x
|
34.3x
|
| EV / EBITDA |
31.0x
|
25.6x
|
| Price / Sales |
7.3x
|
6.6x
|
| Price / FCF |
22.1x
|
22.0x
|
| Revenue Growth YoY |
+12.4%
|
+15.0%
|
| Gross Margin |
70.7%
|
21.3%
|
| Operating Margin |
27.6%
|
5.9%
|
| Return on Equity |
68.0%
|
30.0%
|
| Dividend Yield |
0% |
0.17% |
| FCF Yield |
4.52%
|
4.5%
|
| Analyst Consensus |
Strong Buy
|
Buy
|
Investment Thesis
AbbVie Inc. is a leading healthcare company specializing in drug manufacturing with a strong focus on immunology and aesthetics. The company is transitioning from its historical Humira dominance, which has faced loss of exclusivity, toward high-growth assets like Skyrizi and Rinvoq that are driving robust revenue growth of 12.4% in the most recent quarter. Despite strong revenue growth and a dura…
GE Vernova is the premier pure-play on the electricity side of the AI infrastructure supercycle. Its Power (heavy-duty gas turbines) and Electrification (grid equipment) segments are structurally supply-constrained, backed by a record $176B backlog that management says is 'mostly sold out through 2030.' The company raised FY2026 guidance for a second straight quarter to $45.5-46.5B revenue and $1…
Accumulation Zones
| Metric |
ABBV |
GEV |
| Zone Low |
$198.23 |
$640.00 |
| Zone High |
$224.66 |
$723.00 |
| In Buy Zone? |
No
|
No
|